GERN vs. DVAX, IRWD, LGND, MNKD, INVA, OPK, FOLD, ORGO, INZY, and FHTX
Should you be buying Geron stock or one of its competitors? The main competitors of Geron include Dynavax Technologies (DVAX), Ironwood Pharmaceuticals (IRWD), Ligand Pharmaceuticals (LGND), MannKind (MNKD), Innoviva (INVA), OPKO Health (OPK), Amicus Therapeutics (FOLD), Organogenesis (ORGO), Inozyme Pharma (INZY), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical preparations" industry.
Geron (NASDAQ:GERN) and Dynavax Technologies (NASDAQ:DVAX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.
Geron has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.
Dynavax Technologies has a net margin of -2.75% compared to Geron's net margin of -77,691.14%. Dynavax Technologies' return on equity of -1.08% beat Geron's return on equity.
Geron currently has a consensus price target of $5.33, suggesting a potential upside of 40.72%. Dynavax Technologies has a consensus price target of $25.00, suggesting a potential upside of 123.02%. Given Dynavax Technologies' higher probable upside, analysts plainly believe Dynavax Technologies is more favorable than Geron.
73.7% of Geron shares are owned by institutional investors. Comparatively, 97.0% of Dynavax Technologies shares are owned by institutional investors. 3.1% of Geron shares are owned by insiders. Comparatively, 3.0% of Dynavax Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Geron had 3 more articles in the media than Dynavax Technologies. MarketBeat recorded 6 mentions for Geron and 3 mentions for Dynavax Technologies. Dynavax Technologies' average media sentiment score of 0.73 beat Geron's score of 0.18 indicating that Dynavax Technologies is being referred to more favorably in the news media.
Dynavax Technologies has higher revenue and earnings than Geron. Dynavax Technologies is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.
Geron received 12 more outperform votes than Dynavax Technologies when rated by MarketBeat users. Likewise, 69.53% of users gave Geron an outperform vote while only 65.77% of users gave Dynavax Technologies an outperform vote.
Summary
Dynavax Technologies beats Geron on 10 of the 17 factors compared between the two stocks.
Get Geron News Delivered to You Automatically
Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
